| Local News |
JUNE-JULY , 2021 | THE HEALTH
05
Duopharma Biotech proposes 1-for-3 bonus
DUOPHARMA Biotech Berhad has proposed a one-for-three bonus issue after posting a sterling first quarter ended Mar 31 , 2021 , with profit before tax climbing to RM23.18 million . This is more than 30 per cent from the RM17.73 million posted in the preceding year corresponding period .
This commendable achievement was made against quarterly revenue of RM166.45 million ( 2020 : RM158.71 million ), the company announced to Bursa Malaysia recently .
After accounting for taxation , net profit for the quarter was recorded at RM17.61 million ( 2020 : RM13.56 million ), translating to earnings per share ( EPS ) climbing to 2.49 sen for the quarter , from the 1.98 sen posted previously .
The 1-for-3 proposed bonus issue would entail the issuance of up to 239,926,896 new ordinary shares on an entitlement date to be determined
THE NATIONAL Kidney Foundation of Malaysia ( NKF ) is shocked and appalled by distasteful claims made by two viral social media postings attempting to promote a product to cure kidney disease . NKF was alerted of these scams when members of the public contacted the organisation to enquire about the legitimacy of the product . Further investigation led to the viral postings , which included two different tampered photos of NKF Malaysia that were taken at an event in 2015 and 2019 respectively .
NKF made it clear that it does not endorse such products that promote false claims on curing kidney disease . The postings on social media which promotes Jisheng Kidney Qi Tablets as cure for kidney disease without dialysis is clearly a scam that NKF will not tolerate .
“ We take such scams very seriously , and announced later , and subject to approvals from Bursa Securities , shareholders at a meeting of members to be convened and other relevant authorities .
In the same announcement , the Company also said that , on Feb 22 , 2021 , the Board of Directors had resolved that the Dividend Reinvestment Plan (“ DRP ”) approved by shareholders at the Company ’ s Extraordinary General Meeting on 31 May 2018 would apply to the second interim dividend of 6.0 sen per share amounting to approximately RM42.36 million .
The issue price of the new ordinary shares in the Company to be issued pursuant to the DRP has been fixed at RM3.08 per new Duopharma Biotech Berhad share . The issue price is at a discount of approximately 10 per cent to the 5-day ex-dividend volume weighted average market price
NKF refutes viral postings
is a “ home away from home ”, which aims to fulfil the needs of families of pediatric patients from outside Kuala Lumpur , while helping to alleviate families ’ financial burdens by providing affordable lodging at only RM15 per night in the city .
Located on the 10th floor of the especially ones which portrayed to be endorsed by NKF . We would like to reiterate that we do not endorse products that claim to cure kidney disease , especially ones promoted by external links which are not related to NKF ,” said NKF Malaysia Chairman Dato ’ Dr Zaki Morad Mohamad Zaher .
“ We at NKF provide advice on the prevention and treatment of kidney diseases based on evidence and consultation with our panel of experts . Over the years , there have been multiple claims made by pharmaceutical individuals and others in the medical line about products can prevent kidney disease or cure it . However , the public is advised to verify such claims either with their doctors or NKF first ,” he added .
Following this , NKF has lodged two police reports for the two separate postings and also filed complaints
hospital parking complex , the house is equipped with 20 family rooms , which can accommodate up to 80 occupants , a dining area , lounge area , kitchen , laundry room , prayer room , and playroom , and other facilities . The home is also strategically located in the heart of KL , offering beautiful night views of the city .
“ We at Ronald McDonald House Charities Malaysia ( RMHC ) would like to thank all parties who have made the construction and development of our Ronald McDonald Houses . All houses were funded via donations from McDonald ’ s customers who
( VWAMP ) of RM3.42 .
The entitlement date for the second interim dividend was on Apr 22 , 2021 , whilst the payment date was on May 21 , 2021 . The last day for submission of the Dividend Reinvestment Form was May 10 , 2021 .
Duopharma Biotech Group Managing Director Leonard Ariff Abdul Shatar attributed the stronger financial performance to improved revenue from higher sales to the consumer healthcare sector during the period .
Profit for the quarter also climbed as compared to the previous corresponding period mainly due to increase in sales during the quarter , coupled with forex losses posted in last year ’ s corresponding period .
Looking ahead , he expressed optimism that the Company would continue with its strong financial trajectory for the rest of 2021 .
with the Malaysian Communications and Multimedia Commission ( MCMC ) and Ministry of Health ( MoH ) for further investigation .
NKF further called on irresponsible parties to stop promoting such scams which preys on a patient ’ s emotional and mental state of health , especially during trying times like these as our country battles the ongoing Covid-19 pandemic . It is very irresponsible thing to do and promoting scams like these is unethical and immoral .
For credible information about kidney disease , treatment options , medications and to get the latest updates , do visit NKF Malaysia ’ s official website www . nkf . org . my or send an email to info @ nkf . org . my .
contributed through the RMHC coin box located at more than 300 McDonald ’ s restaurants nationwide as well as contributions from McDonald ’ s employees , business partners and franchisees .
“ Thank you for your generosity towards our mission to change the lives of Malaysian children . RMHC Malaysia will continue to champion the needs of Malaysian children through the funds we receive from generous Malaysians ,” said Azmir Jaafar , President of Ronald McDonald House Charities Malaysia as well as Managing Director and Local Operating Partner of McDonald ’ s Malaysia .
Briefs
KPJ Healthcare appointed for vaccination programme
KPJ Healthcare Berhad ( KPJ ) has been appointed by ProtectHealth Corporation ( ProtectHealth ) to administer Covid-19 vaccination at the Covid-19 Vaccination Centre Mega ( PPV Mega ) Kuala Lumpur Convention Centre ( KL Convex ) from June 7 , 2021 .
This PPV Mega is organised by the Covid-19 Immunisation Task Force ( CITF ) as part of the National Covid-19 Immunisation Programme ( NIP ).
At the PPV Mega KL Convex , KPJ will be administering up to 2,600 vaccinations daily , or about a third of the targeted total 8,000 doses daily at the centre .
In addition to this , KPJ , through 20 of its hospitals nationwide , is participating in the Private Hospital Covid-19 Vaccination Centre ( PPVHS ) scheme and will be administering up to 3,400 doses daily by the end of June 2021 .
In total , KPJ will be administering up to 6,000 doses of Covid-19 vaccination daily by the end of June 2021 .
These vaccinations will be at PPV Mega at KL Convex and the 20 KPJ hospitals and will account for four per cent of the targeted national daily vaccination of 150,000 , the largest number of vaccinations daily by a private healthcare group in Malaysia .
Conditional registration for hepatitis C treatment
THE MINISTRY of Health ( MoH ) has informed that the Drug Control Authority ( DCA ) Malaysia has granted a conditional registration for Ravida ® Tablet 200mg ( Ravidasvir Hydrochloride 200mg ) in their 358th meeting on June 4 , 2021 .
Malaysia is the first country in the world to approve the use of Ravida ®, which is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus ( HCV ) infection in adults .
The product is manufactured by the Doppel Farmaceutici S . R . L , Italy with Pharmaniaga Manufacturing Berhad as the product registration holder in Malaysia .
HCV infection is considered as a public health issue whereby Malaysia is committed to the goal to eliminate HCV by 2030 . However , the cost of screening and the currently available Direct Acting Antivirals ( DAAs ) are expensive and there is a need to search for alternative treatments and solutions .
The National Strategic Plan for Hepatitis B & C 2019-2023 was developed by MoH to clearly strategise and to ensure the goal to eliminate hepatitis B and C is achievable .